Evidence map›Paper›PMID 41542033›Full record

ArticleMolecular therapy. Oncology2026

Safety and feasibility of talimogene laherparepvec in peritoneal surface malignancies: Results from the TEMPO trial.

John H Stewart, Donna Niedzwiecki, Melissa Lowe, Ashley Moyer, Emily Bolch, Shannon Diane MacLaughlan, Edward A Levine, Omeed Moaven, Niharika Mettu, John H Strickler and 1 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03663712 (A Phase I Trial of Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03663712 phase1completednot on this map

A Phase I Trial of Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies

TypeinterventionalSponsorDan Blazer III, M.D.Ran2019 to 2022Enrolled28ConditionsPeritoneal Surface MalignancyArmsTalimogene Laherparepvec
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

John H StewartMorehouse School of Medicine, Department of Surgery, Atlanta, GA 30310, USA.
Donna NiedzwieckiDuke Cancer Institute, Durham, NC 27710, USA.
Melissa LoweDuke Cancer Institute, Durham, NC 27710, USA.
Ashley MoyerDuke University School of Medicine, Department of Pathology, Durham, NC 27710, USA.
Emily BolchDuke Cancer Institute, Durham, NC 27710, USA.
Shannon Diane MacLaughlanThe University of Illinois at Chicago Department of Obstetrics and Gynecology, Chicago, IL 60612, USA.
Edward A LevineWake Forest University School of Medicine, Department of Surgery, Winston-Salem, NC 27157, USA.
Omeed MoavenThe Louisiana State University School of Medicine, Department of Surgery, New Orleans, LA 70112, USA.
Niharika MettuDuke Cancer Institute, Durham, NC 27710, USA.
John H StricklerDuke Cancer Institute, Durham, NC 27710, USA.
Dan G BlazerDuke Cancer Institute, Durham, NC 27710, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Peritoneal surface malignancies (PSMs) remain a therapeutic challenge, particularly in patients with unresectable disease who cannot benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. The Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies (TEMPO) trial (NCT03663712) is the first phase 1, multicenter, open-label study to evaluate intraperitoneal (i.p.) administration of talimogene laherparepvec (T-VEC), an FDA-approved oncolytic virus, in this setting. Nineteen patients with unresectable PSMs from appendiceal, ovarian, small bowel, and peritoneal carcinomas were enrolled; 18 received treatment across three escalating dose cohorts (4 × 10

Indexed as

biosafety and viral sheddingcytoreductive surgery alternativesdose-escalation trialintraperitoneal therapylocoregional immunotherapyMT: Regular Issueoncolytic virotherapyperitoneal surface malignanciesphase 1 clinical trialtalimogene laherparepvec T-VECviral kinetics

Identifiers

PMID41542033
PMCPMC12800498

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.